Clinical Trials Browser

INDUSTRY × Interventional × Neuroendocrine Tumors × Clear all

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03093116 2026-05-27

TRIDENT-1

Phase 1/2 Recruiting

500 enrolled 2 FDA

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07377487 2026-05-22

INDIGO

Phase NA Recruiting

51 enrolled

EndocrineGastrointestinalNET

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

98 enrolled

EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Phase 1/2 Recruiting

300 enrolled

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Clinical Trials

STARTRK-2

TRIDENT-1

INDIGO

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

BRAVESST2

KinLET

CAREFNDR

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

STELLAR-311

ALPHAMEDIX02

DeLLphi-307

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

COMPETE

ACTION-1

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

MK-6070-001

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Sapu003 in Advanced mTOR-sensitive Solid Tumors

ODYSSEY

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

KEYNOTE 158

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Open-label Study of Surufatinib in Japanese Patients

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

COMPOSE

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Open-Label Surufatinib in European Patients With NET

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

ARROW

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Study of rSIFN-co for Patients With Advanced Solid Tumors

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NETest_Sx

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

ALpha-T